Scholars@Duke
Susan Halabi

Susan Halabi CV

James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
susan.halabi@duke.edu
Duke Box 2717, Durham, NC 27710
2424 Erwin Road 11th Floor, 11088 Hock Plaza, Durham, NC 27705
CV

Scholarly Works - Conferences

Patterns of poly(ADP-ribose) polymerase inhibitor use and overall survival in United States veterans with prostate cancer.

Conference Journal of Clinical Oncology · June 1, 2026 e17049Background: PARP inhibitors (PARPi) are life-prolonging therapies for men with ... Full text Cite

Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with ERBB2 alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study.

Conference Journal of Clinical Oncology · June 1, 2026 3104Background: TAPUR is a phase II basket study evaluating the antitumor activity of ... Full text Cite

Analysis of genomic and clinical predictors of overall survival and PSA response: Results from the PRECISION registry.

Conference Journal of Clinical Oncology · June 1, 2026 5051Background: Outcomes in advanced prostate cancer vary substantially according to ... Full text Cite

Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).

Conference Journal of Clinical Oncology · June 1, 2026 5016Background: Platinum-doublet chemotherapy is effective in pts with neuroendocrine ... Full text Cite

Abstract CT211: Palbociclib (P) in patients (pts) with lung cancer (LC) with CCND1 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · April 17, 2026 AbstractBackground:TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in ... Full text Cite

Abstract CT206: Larotrectinib (L) in patients (pts) with solid tumors with NTRK1/2/3 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · April 17, 2026 AbstractBackground:TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in ... Full text Cite

Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference JCO Precision Oncology · April 1, 2026 PURPOSE – TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations who have no standard treatments available. Results of four cohorts of patients w ... Full text Cite

Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.

Conference Journal of Clinical Oncology · March 1, 2026 382 Background: Androgen receptor signaling drives prostate cancer (PC) progression, and genes involved in androgen production, uptake, and conversion (APUC) are key therapeutic targets. We previously defined a 6-APUC gene set (HSD3B1, HSD3B2, CYP3A43, CYP ... Full text Cite

Trial design and objectives for prostate cancer: Recommendations from the Prostate Cancer Clinical Trials Working Group 4 (PCWG4).

Conference Journal of Clinical Oncology · March 1, 2026 162Background: Clinical trial conduct in advanced prostate cancer has changed dramati ... Full text Cite

Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 alterations (alts): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · January 10, 2026 127Background: TAPUR is a phase II basket study evaluating antitumor activity of comm ... Full text Cite

Abstract C117: Serum dehydroepiandrosterone sulfate (DHEAS) and race associated with longer survival in patients (pts) treated with apalutamide (Apa) and abiraterone acetate (AA) plus prednisone (P) in the PANTHER study

Conference Cancer Epidemiology, Biomarkers & Prevention · September 18, 2025 AbstractBackground:PANTHER is a multicenter prospective trial of Black and White cohorts of metastatic castration-resistant prostate c ... Full text Cite

Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.

Conference Journal of Clinical Oncology · June 2025 e17076Background: PANTHER is a multicenter prospective trial of Black and White cohorts of metastatic castration resistant pr ... Full text Cite

Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men.

Conference Journal of Clinical Oncology · June 2025 5082Background: Multiple reports suggest that Black patients with mCRPC have different responses to radiation, immunotherapy, ... Full text Cite

Does cytoplasmic AR-V7 circulating tumor cell (CTC) detection add utility in predicting AR pathway inhibitor benefit in men with mCRPC? A retrospective analysis of the PROPHECY study.

Conference Journal of Clinical Oncology · June 2025 5043Background: Androgen receptor splice variant-7 (AR-V7) is a constitutively active truncated protein that emerges during h ... Full text Cite

Pertuzumab plus trastuzumab (P+T) in patients (pts) with bladder (BC) and ovarian cancer (OC) with ERBB2/3 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · June 2025 3126Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in p ... Full text Cite

Overall survival outcomes with sipuleucel-T (Sip-T) among Black men with metastatic castrate-resistant prostate cancer (mCRPC) also treated with androgen receptor pathway inhibitors (ARPI).

Conference Journal of Clinical Oncology · June 2025 e17064Background: Analyses of clinical trials data suggest thatBlack men have equal or even improved overall survival (OS) wi ... Full text Cite

Suboptimal suppression of serum androgen levels among men treated with apalutamide and abiraterone acetate plus prednisone compared with abiraterone acetate plus prednisone alone.

Conference Journal of Clinical Oncology · June 2025 5065Background: Phase III studies of dual therapy with an androgen receptor (AR) antagonist, apalutamide (Apa) or enzalutamid ... Full text Cite

Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · June 2025 e17660Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in ... Full text Cite

Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · April 25, 2025 AbstractBackground:TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts wit ... Full text Cite

Abstract CT226: Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · April 25, 2025 AbstractBackground:TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts wit ... Full text Cite

Can magnetic resonance imaging safely replace a confirmatory biopsy in patients on active surveillance for prostate cancer?

Conference Journal of Clinical Oncology · February 10, 2025 331Background: Active surveillance (AS) is recognized as the preferred management for patients with low-risk prostate cancer, ... Full text Cite

A natural language processing algorithm to extract MRI and biopsy-related phenotypes for prostate cancer patients.

Conference Journal of Clinical Oncology · February 10, 2025 356Background: Extraction of data from unstructured medical records is a powerful but challenging tool for deriving novel inf ... Full text Cite

Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).

Conference Journal of Clinical Oncology · February 10, 2025 309Background: Standard of care (SOC) treatment options for HR-PCa include RT with long-term androgen deprivation (LT-ADT) or ... Full text Cite

Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial.

Conference Journal of Clinical Oncology · February 10, 2025 246Background: Serum androgen levels are prognostic in mCRPC and genetic variation in androgen metabolism may drive these eff ... Full text Cite

Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP) (Alliance).

Conference Journal of Clinical Oncology · February 10, 2025 230Background: DHEA, testosterone (T) and androstenedione (AD) are adrenal androgens that can drive CRPC. Full text Cite

Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · February 10, 2025 154Background: In 2004, docetaxel (DOC), a semi-synthetic taxane, received regulatory approval for mCRPC based on improved ov ... Full text Cite

Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · February 2025 715Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pt ... Full text Cite

Abstract B066: Analytical validation of a multiplexed CTC-mRNA assay for androgen receptor pathway inhibitors

Conference Clinical Cancer Research · November 13, 2024 AbstractIntroduction: Androgen receptor pathway inhibitors (ARPIs) have been shown to improve survival for men with metastatic prostate cancer, however, the use of 2nd line ARPIs has limited efficacy. There ... Full text Cite

Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.

Conference JCO Precis Oncol · June 2024 PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. R ... Full text Link to item Cite

Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · June 1, 2024 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a small cohort of pts with advanced solid tumors with NRG1 fusions treate ... Full text Cite

Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · June 1, 2024 3142Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with advanced solid tumors with ERBB2/3amp or mut tre ... Full text Cite

Abstract CT268: Palbociclib (P) in patients (pts) with solid tumors with CCND1 amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · April 5, 2024 AbstractBackground: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohor ... Full text Cite

Abstract CT267: Temsirolimus (T) in patients (pts) with solid tumors with AKT1/3 amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · April 5, 2024 AbstractBackground: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohor ... Full text Cite

AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.

Conference Journal of Clinical Oncology · February 1, 2024 LBA531Background: Muscle-invasive urothelial carcinoma (MIUC) is an aggressive disease with high relapse rates. Neoadjuvant platinum-based chemotherapy (NAC) is the standard of care in patients (pts) who are cisplatin (Cis)-eligible. However, many pts are ... Full text Cite

Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · January 20, 2024 308Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with EC with CDKN2A loss or mut treated with ... Full text Cite

Olaparib in Patients with Pancreatic Cancer with BRCA1 / 2 Mutations: Results from the Targeted Agent and Profiling Utilization Registry Study

Conference JCO Precision Oncology · January 1, 2024 PURPOSETargeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Resul ... Full text Cite

Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.

Conference Journal of Clinical Oncology · January 1, 2024 Background: In pts with nmCRPC, metastatic progression was not consistently associated with PSA progression in a prior analysis of ARAMIS (Morgans AK, et al. J Clin Oncol 2022;40:5044). We evaluated prostate cancer (PC)-specific survival in ARAMIS, and the ... Full text Cite

Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Journal of Clinical Oncology · January 1, 2024 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with advanced solid tumors with HTMB treated with N+I are ... Full text Cite

A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial

Conference Journal of Clinical Oncology · January 1, 2024 Background: Over the last six decades, platinum-based chemotherapy has been the standard of care first-line treatment for advanced penile squamous cell carcinoma (PSCC). Advanced PSCC has poor prognosis with limited treatment options. Immune checkpoint inh ... Full text Cite

Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · January 1, 2024 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with CRC with BRCA1/2 mut treated with Tala are ... Full text Cite

1837P Assessing PSA

Conference Annals of Oncology · October 2023 Full text Cite

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Conference JCO Precis Oncol · September 2023 PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. The ... Full text Link to item Cite

A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.

Conference Journal of Clinical Oncology · June 1, 2023 5015 Background: Abi Race was the first prospective parallel cohort study of abiraterone acetate plus prednisone (AAP) in Black and White men with metastatic castrate-resistant prostate cancer (mCRPC) and demonstrated greater pro ... Full text Cite

The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.

Conference Journal of Clinical Oncology · June 1, 2023 5060 Background: It has been shown that HOXB13 is an important androgen receptor (AR) coregulator. The primary objective of this analysis was to correlate HOXB13 expression with clinical outcomes in men with mCRPC. Methods: We co ... Full text Cite

Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · June 1, 2023 5548 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with OC with BRCA1/2 mut ... Full text Cite

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Conference Journal of Clinical Oncology · June 1, 2023 5070 Background: Prior data have shown that prostate specific antigen (PSA) ≤ 0.2 ng/dL at 6-7 months with androgen deprivation therapy (ADT) with testosterone suppression (TS) alone is prognostic of OS. We hypothesized that PSA ... Full text Cite

Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · June 1, 2023 3115 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumor ... Full text Cite

Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · June 1, 2023 3117 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in cohorts of pts with breast cancer (BC) an ... Full text Cite

The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).

Conference Journal of Clinical Oncology · June 1, 2023 5073 Background: Prior analyses have shown that men who present with high volume (HV) disease and de novo metastases have shorter OS compared with other mHSPC subgroups. The objective of this analysis was to determine the prognos ... Full text Cite

Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).

Conference Journal of Clinical Oncology · June 1, 2023 5077 Background: In the phase 3 PRESTO study, intensified androgen deprivation therapy (ADT) with apalutamide (Apa) with or without abiraterone acetate plus prednisone (AAP), administered for a finite treatment period of 52 weeks ... Full text Cite

Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · April 14, 2023 AbstractBackground: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohor ... Full text Cite

Abstract CT231: Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · April 14, 2023 AbstractBackground: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohor ... Full text Cite

Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.

Conference Urol Oncol · November 2022 PURPOSE: Hypoxia inducible factor (HIF) pathway alterations drive progression of clear cell renal cell carcinoma (ccRCC). We aim to evaluate genes within the canonical and non-canonical HIF pathways as predictors of survival in metastatic ccRCC. MATERIALS ... Full text Link to item Cite

Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.

Conference Journal of Clinical Oncology · February 20, 2022 139 Background: Androgen receptor signaling inhibitors (ARSi) are a mainstay for patients with metastatic castration-resistant prostate cancer (mCRPC). However, patient response is heterogeneous and the molecular underpinnings of ... Full text Cite

HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC).

Conference Journal of Clinical Oncology · February 20, 2022 370 Background: Clear cell renal cell carcinoma (ccRCC) is characterized by defects in the Von Hippel-Lindau/hypoxia-inducible factor (VHL/HIF) pathway. Several FDA-approved RCC therapies target the products of HIF-response genes ... Full text Cite

Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · February 1, 2022 107 Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of CRC pts with hTMB treated ... Full text Cite

Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Conference Journal of Clinical Oncology · February 1, 2022 106 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of CRC pts with PIK3CA mutation ... Full text Cite

Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Androgen deprivation therapy (ADT) and radiotherapy (RT) are synergistic, and the combination results in improved survival outcomes for aggressive prostate cancers. However, long-term ADT carries substantial burden of toxicity ... Full text Cite

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Conference J Clin Oncol · August 1, 2021 PURPOSE: The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a cohort ... Full text Link to item Cite

Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.

Conference Mol Cancer Res · June 2021 Men with circulating tumor cell (CTC) AR-V7-positive metastatic castration-resistant prostate cancer (mCRPC) have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and additional predictive biomarkers ar ... Full text Link to item Cite

Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.

Conference Journal of Clinical Oncology · May 20, 2021 5057 Background: Radiographic progression-free survival (rPFS) is commonly used as a co-primary endpoint in randomized clinical trials in men with metastatic castrate-resistant prostate cancer (mCRPC). However, rPFS has not been ... Full text Cite

Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).

Conference Journal of Clinical Oncology · February 20, 2021 154 Background: CALGB 90401 was a phase III trial of 1050 pts with mCRPC comparing DP+B versus DP alone. While this trial did not show an improvement in OS in the overall population, there were improved PSA response, objective re ... Full text Cite

Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

Conference Journal of Clinical Oncology · February 20, 2021 157 Background: We evaluated the prognostic significance of circulating tumor cell (CTC) number as determined on the Epic Sciences platform in men with metastatic castration resistant prostate cancer (mCRPC) treated with an andro ... Full text Cite

Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.

Conference Journal of Clinical Oncology · February 20, 2021 89 Background: Men with metastatic neuroendocrine/small cell and aggressive variant prostate cancer (NEPC/AVPC) have poor outcomes despite platinum and taxane chemotherapy. These tumors share common features with small cell lung ... Full text Cite

Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).

Conference Journal of Clinical Oncology · February 20, 2021 39 Background: The presence of progressing cancer, male sex and advanced age have been shown to increase the severity of coronavirus disease 2019 (COVID-19). Given that the androgen regulated gene TMPRSS2 has been implicated in S ... Full text Cite

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

Conference Eur Urol · April 2020 BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prosta ... Full text Link to item Cite

AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY

Conference JOURNAL OF CLINICAL ONCOLOGY · February 20, 2020 Link to item Cite

Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.

Conference Journal of Clinical Oncology · February 1, 2020 122 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of CRC pts with BRAF V600E mutat ... Full text Cite

Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.

Conference Journal of Clinical Oncology · February 1, 2020 132 Background: TAPUR is a phase II basket trial evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of CRC pts with ERBB2 overexpres ... Full text Cite

Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Conference JCO Precis Oncol · December 2019 PURPOSE: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that harbor genomic alterations known as drug targets. In this ... Full text Link to item Cite

Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reported KRAS, NRAS, BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · July 1, 2019 AbstractBackground: The TAPUR Study is a phase II multi-basket study that evaluates the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations ... Full text Cite

Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) with FLT-3 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Conference Cancer Research · July 1, 2019 AbstractBackground: TAPUR is a phase II multi-basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations known to be dr ... Full text Cite

Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · May 20, 2019 e16579 Background: PM’s in mCRPC accurately predict survival, but little is known about their association with QOL. We hypothesize that pre-treatment QOL is inversely correlated with PM derived scores. Our study explored associat ... Full text Cite

External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · May 20, 2019 5022 Background: We have previously developed and externally validated a prognostic model of OS in men with mCRPC treated with docetaxel (D), which included eight predictors: opioid analgesic use, ECOG performance status, albumin ... Full text Cite

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · May 20, 2019 5008 Background: Androgen receptor (AR) signaling is an important growth mechanism in mCRPC, providing the rationale for treatment with AR axis inhibitors such as ENZ and AAP. Targeting AR with anti-androgens such as ENZ can resu ... Full text Cite

CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).

Conference Journal of Clinical Oncology · May 20, 2019 5079 Background: Neoadjuvant CHT followed by RP did not increase 3-year biochemical progression free-survival (bPFS) compared to RP alone in men with CLHRPC. However, there is evidence that bPFS and overall survival over time was ... Full text Cite

PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · May 20, 2019 5021 Background: We have shown previously in multivariable analysis that AA men had 19% lower risk of death than C men with metastatic castration resistant prostate cancer (mCRPC) treated with a docetaxel (D) and prednisone (P) b ... Full text Cite

CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.

Conference Journal of Clinical Oncology · May 20, 2019 4503 Background: The combination of gemcitabine (G) and cisplatin (C) is a standard therapy for metastatic urothelial carcinoma (mUC). Based on data that angiogenesis plays a role in UC growth and progression, a randomized placeb ... Full text Cite

Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Conference Journal of Clinical Oncology · May 20, 2019 1014 Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. P is an immune checkpoint inhibitor an ... Full text Cite

Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · March 1, 2019 186 Background: We have previously shown in multivariable analysis that African American (AA) men had 19% lower risk of death than Caucasian (C) men with metastatic castration resistant prostate cancer (mCRPC) treated with a doce ... Full text Cite

Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.

Conference Journal of Clinical Oncology · February 20, 2018 11 Background: Combined external beam radiotherapy (RT) and androgen deprivation therapy (ADT) improves survival over RT alone for high risk prostate cancer (PC). Long-term ADT use, currently recommended for high risk PC, also in ... Full text Cite

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.

Conference Journal of Clinical Oncology · February 20, 2018 582 Background: The randomized phase 2 CABOSUN trial (NCT01835158) compared cabozantinib (C) with sunitinib (S) as initial systemic therapy in patients (pts) with RCC of intermediate or poor risk. Compared with S, C improved both ... Full text Cite

Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.

Conference Journal of Clinical Oncology · February 20, 2018 160 Background: Radium-223 is a targeted alpha therapy that improves survival in men with mCRPC. The biologic basis for radium-223 efficacy is not completely understood. We hypothesized that PC osteomimicry, a form of epithelial ... Full text Cite

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.

Conference Clin Cancer Res · November 15, 2017 Purpose: The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT) has become a standard treatment for patients with metastatic prostate cancer. The recently accrued phase III CALGB 90203 trial was designed to investigate the clinica ... Full text Link to item Cite

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

Conference Eur J Cancer · August 2017 BACKGROUND: Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. METHODS: This was a multisite single ar ... Full text Link to item Cite

Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.

Conference Journal of Clinical Oncology · May 20, 2017 5034 Background: Loss of the retinoblastoma tumor suppressor (RB) function was identified as a major means to develop CRPC; the expression of the androgen receptor (AR) is under stringent RB control; and tumors devoid of RB funct ... Full text Cite

Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).

Conference Journal of Clinical Oncology · May 20, 2017 4522 Background: Elevated baseline HGF levels were associated with shorter OS in pts treated with BEV+INF. We evaluated on-treatment HGF levels to describe treatment-related changes and associations with outcome. Methods: We anal ... Full text Cite

Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance).

Conference Journal of Clinical Oncology · May 20, 2017 5067 Background: Higher baseline androgens have been previously shown to be associated with an improved overall survival (OS) in mCRPC patients treated with the androgen synthesis inhibitors, ketoconazole or abiraterone. The purp ... Full text Cite

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.

Conference Prostate · March 2017 BACKGROUND: Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent a ... Full text Link to item Cite

Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Conference Cancer Research · July 15, 2016 AbstractBackground: Treatment-related GI HEM is a major health concern with few known predictive risk factors. The objective of this analysis was to discover clinical and genetic factors that modulate GI HEM ... Full text Cite

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.

Conference Prostate Cancer Prostatic Dis · March 2016 BACKGROUND: In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiother ... Full text Link to item Cite

Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · January 10, 2016 275 Background: Docetaxel prednisone (DP) is a standard of care for men with metastatic castrate resistant prostate cancer (mCRPC) with median progression-free survival (PFS) of 4-6 months and overall survival (OS) of 19 months, ... Full text Cite

Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE)

Conference Cancer Research · October 1, 2014 AbstractBackground BEV is associated with an increased risk of ATE, however, its effect on VTE remains controversial. We investigated the association of BEV treatment and clinical risk factors with the incid ... Full text Cite

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Conference Journal of Clinical Oncology · February 20, 2013 105 Background: PTEN loss is common in advanced prostate cancer, leading to constitutive activation of the PI3 Kinase pathway. Temsirolimus blocks mTOR/TORC1, a key signaling node in this pathway; its activity in men with advance ... Full text Cite

Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).

Conference Journal of Clinical Oncology · February 20, 2013 27 Background: Zoledronic acid (ZA) decreases risk of skeletal-related events (SREs) in men with castration-resistant prostate cancer (CRPC) and bone metastases. This phase III study evaluated efficacy and safety of earlier treat ... Full text Cite

Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · February 10, 2012 200 Background: Baseline pain has been shown to be a significant predictor of overall survival (OS) in mCRPC pts. The objectives of this analysis were to identify predictors of OA use at 3-months after initiating frontline chemot ... Full text Cite

2230

Conference International Journal of Radiation Oncology*Biology*Physics · November 2006 Full text Cite

CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.

Conference Blood · November 16, 2004 AbstractA graft-versus-tumor effect mediated by non-myeloablative allogeneic stem cell transplantation has been reported for patients with cytokine-refractory, metastatic renal cell carcinoma (RCC). An Inter ... Full text Cite

Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.

Conference CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION · November 1, 2004 Link to item Cite

A case-control study of candidate ovarian cancer susceptibility polymorphisms.

Conference CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION · October 1, 2002 Link to item Cite